

Thomas A Hope

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3462533/publications.pdf>

Version: 2024-02-01

178
papers

9,075
citations

44444

50
h-index

54771

88
g-index

184
all docs

184
docs citations

184
times ranked

9330
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comprehensive Assessment of ⁶⁸ Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 567-572.	2.8	20
2	Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. <i>Surgery</i> , 2022, 171, 47-54.	1.0	13
3	A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. <i>Surgery</i> , 2022, 171, 55-62.	1.0	8
4	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
5	Attenuation Coefficient Estimation for PET/MRI With Bayesian Deep Learning Pseudo-CT and Maximum-Likelihood Estimation of Activity and Attenuation. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2022, 6, 678-689.	2.7	4
6	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 76-80.	2.8	20
7	Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. <i>Pancreatology</i> , 2022, 22, 123-129.	0.5	6
8	Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. <i>Biosensors and Bioelectronics</i> , 2022, 199, 113854.	5.3	10
9	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2022, 40, 1500-1505.	0.8	16
10	Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. <i>Lancet Oncology</i> , 2022, 23, e75-e87.	5.1	26
11	PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point? Reply. <i>JAMA Oncology</i> , 2022, , .	3.4	0
12	Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging.. <i>Journal of Clinical Oncology</i> , 2022, 40, 109-109.	0.8	0
13	Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 167-167.	0.8	0
14	The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263448.	2.8	20
15	Leadership in Patient Advocacy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 497-499.	2.8	0
16	Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 352-359.	1.8	10
17	ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 233-242.	0.6	3
18	ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. <i>Clinical Nuclear Medicine</i> , 2022, 47, 503-511.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2818-2829.	0.8	13
20	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5043-5043.	0.8	5
21	Intraarterial Peptide Receptor Radionuclide Therapy Using ^{90}Y -DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2021, 62, 221-227.	2.8	9
22	MR-Based Attenuation Correction for Brain PET Using 3-D Cycle-Consistent Adversarial Network. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2021, 5, 185-192.	2.7	22
23	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 174-185.	0.4	77
24	Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center. <i>Journal of Nuclear Medicine</i> , 2021, 62, 695-699.	2.8	21
25	Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 62-69.	1.3	0
26	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	3.3	30
27	Assessment and Comparison of ^{18}F -Fluorocholine PET and $^{99\text{m}}\text{Tc}$ -Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1285-1291.	2.8	21
28	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. <i>Journal of Nuclear Medicine</i> , 2021, 62, 146-148.	2.8	15
29	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638.	3.3	188
30	PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. <i>Lancet, The</i> , 2021, 397, 768-769.	6.3	5
31	Accuracy of ^{18}F -Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1511-1516.	2.8	15
32	The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 258-266.	1.6	19
33	High-Specific-Activity- ^{131}I -MIBG versus ^{177}Lu -DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42
34	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. <i>European Urology Focus</i> , 2021, 7, 238-240.	1.6	31
35	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. <i>Pancreas</i> , 2021, 50, 469-493.	0.5	55
36	More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 563.	3.4	1

#	ARTICLE	IF	CITATIONS
37	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	3.6	38
38	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
39	A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4463-4471.	3.3	9
40	Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1323-1329.	2.8	31
41	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3130-3143.	0.6	9
42	Perspectives on Radiopharmaceutical Agents from the FDA. <i>Journal of Nuclear Medicine</i> , 2021, 62, 881-883.	2.8	1
43	RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1438-1439.	2.8	0
44	Evaluation of attenuation correction in PET/MRI with synthetic lesion insertion. <i>Journal of Medical Imaging</i> , 2021, 8, 056001.	0.8	3
45	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	3.4	138
46	Pitfalls on PET/MRI. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 529-539.	2.5	11
47	Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. <i>Physics in Medicine and Biology</i> , 2021, 66, 035016.	1.6	17
48	Harmonization of PET image reconstruction parameters in simultaneous PET/MRI. <i>EJNMMI Physics</i> , 2021, 8, 75.	1.3	2
49	Response to "Preoperative localization in primary hyperparathyroidism: Views from the developing world" Surgery, 2021, , .	1.0	0
50	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 12S-22S.	2.8	14
51	Can the Injected Dose Be Reduced in ⁶⁸ Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193.	2.8	19
52	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1-33.	0.5	226
53	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	0.5	88
54	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	0.5	58

#	ARTICLE	IF	CITATIONS
55	PET/Magnetic Resonance Imaging Applications in Abdomen and Pelvis. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 369-380.	0.6	9
56	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	2.8	74
57	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine, 2020, 61, 1094-1095.	2.8	6
58	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 2020, 49, 723-728.	0.5	6
59	A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope. Journal of Nuclear Medicine, 2020, 61, 477-479.	2.8	1
60	Bone material analogues for PET/MRI phantoms. Medical Physics, 2020, 47, 2161-2170.	1.6	8
61	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	0.8	107
62	NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2020, 61, 222-227.	2.8	77
63	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	2.8	10
64	Factors Predicting Metastatic Disease in ⁶⁸ Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1779-1785.	2.8	15
65	Gallium-68 prostate-specific membrane antigen ([⁶⁸ Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study. EJNMMI Research, 2020, 10, 128.	1.1	22
66	⁶⁸ Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality. EJNMMI Physics, 2020, 7, 54.	1.3	3
67	Accuracy of ⁶⁸ Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study.. Journal of Clinical Oncology, 2020, 38, 5502-5502.	0.8	18
68	Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2020, 38, 24-24.	0.8	5
69	From Compassionate Use to Phase 3 Trial: The Impact of Germany's PSMA-617 Literature (perspective on) Tj ETQq1 1 0.784314 r g B 255S-262S.	2.8	8
70	Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET. Journal of Nuclear Medicine, 2020, 61, 1764-1764.	2.8	10
71	Introduction to the D-SPECT for Technologists: Workflow Using a Dedicated Digital Cardiac Camera. Journal of Nuclear Medicine Technology, 2020, 48, 297-303.	0.4	9
72	Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. Abdominal Radiology, 2019, 44, 3508-3517.	1.0	22

#	ARTICLE	IF	CITATIONS
73	Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. <i>Molecular Pharmaceutics</i> , 2019, 16, 3831-3841.	2.3	36
74	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	3.3	265
75	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , 2019, 20, 1286-1294.	5.1	338
76	NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2019, 60, 937-943.	2.8	95
77	Author Reply. <i>Urology</i> , 2019, 129, 163-164.	0.5	1
78	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 685-690.	2.6	21
79	What is the best PET target for early biochemical recurrence of prostate cancer? Authors' reply. <i>Lancet Oncology</i> , 2019, 20, e609-e610.	5.1	4
80	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	3.2	190
81	The use of PET/MRI for imaging rectal cancer. <i>Abdominal Radiology</i> , 2019, 44, 3559-3568.	1.0	19
82	Single-Center Prospective Evaluation of ⁶⁸ Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. <i>American Journal of Roentgenology</i> , 2019, 213, 266-274.	1.0	18
83	Mucinous rectal cancer: concepts and imaging challenges. <i>Abdominal Radiology</i> , 2019, 44, 3569-3580.	1.0	35
84	¹¹¹ In-Pentetreotide Scintigraphy Versus ⁶⁸ Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1266-1269.	2.8	66
85	Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. <i>Urology</i> , 2019, 129, 165-171.	0.5	41
86	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
87	AUTHOR REPLY. <i>Urology</i> , 2019, 125, 161-162.	0.5	0
88	Intertumoral Heterogeneity of ¹⁸ F-FDG and ⁶⁸ Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. <i>Clinical Nuclear Medicine</i> , 2019, 44, e28-e32.	0.7	19
89	Ectopic Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma of the Nasopharynx Diagnosed by Gallium 68 DOTATATE Positron Emission Tomography/Computed Tomography. <i>World Neurosurgery</i> , 2019, 125, 400-404.	0.7	17
90	Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 948-952.	0.5	14

#	ARTICLE	IF	CITATIONS
91	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plans in Patients With Prostate Cancer. <i>Urology</i> , 2019, 125, 154-162.	0.5	20
92	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 910-916.	2.8	35
93	Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019, 79, 244-258.	1.2	13
94	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e53-e55.	0.9	8
95	Metaanalysis of ⁶⁸ Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2019, 60, 786-793.	2.8	169
96	Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).. <i>Journal of Clinical Oncology</i> , 2019, 37, 363-363.	0.8	22
97	Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period. <i>Endocrine Connections</i> , 2019, 8, 1149-1158.	0.8	5
98	Zero TE-based pseudo-CT image conversion in the head and its application in PET/MR attenuation correction and MR-guided radiation therapy planning. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1440-1451.	1.9	80
99	MRI Contrast Agents. , 2018, , 41-51.		0
100	Hepatobiliary and Pancreatic Cancer PET/MRI. , 2018, , 281-290.		0
101	Letter to the editor response. <i>Abdominal Radiology</i> , 2018, 43, 239-239.	1.0	0
102	LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2018, 43, 149-157.	1.0	82
103	Zero-Echo-Time and Dixon Deep Pseudo-CT (ZeDD CT): Direct Generation of Pseudo-CT Images for Pelvic PET/MRI Attenuation Correction Using Deep Convolutional Neural Networks with Multiparametric MRI. <i>Journal of Nuclear Medicine</i> , 2018, 59, 852-858.	2.8	206
104	Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 66-74.	2.8	228
105	Motion robust high resolution 3D free-breathing pulmonary MRI using dynamic 3D image self-navigator. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 2954-2967.	1.9	53
106	Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2018, 43, 1627-1633.	1.0	57
107	LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. <i>Abdominal Radiology</i> , 2018, 43, 56-74.	1.0	58
108	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed mITNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	2.8	372

#	ARTICLE	IF	CITATIONS
109	Variable refocusing flip angle single-shot fast spin echo imaging of liver lesions: increased speed and lesion contrast. <i>Abdominal Radiology</i> , 2018, 43, 593-599.	1.0	2
110	Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction. <i>Molecular Imaging</i> , 2018, 17, 153601211881174.	0.7	6
111	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. <i>Radiology</i> , 2018, 289, 730-737.	3.6	114
112	Does Extended PET Acquisition in PET/MRI Rectal Cancer Staging Improve Results?. <i>American Journal of Roentgenology</i> , 2018, 211, 896-900.	1.0	23
113	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	1.0	25
114	PET/MRI for Gastrointestinal Imaging. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 691-714.	1.0	5
115	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2045-2054.	3.3	116
116	PET/MR Imaging of the Pancreas. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 345-362.	0.6	6
117	Clinical Evaluation of ⁶⁸ Ga-PSMA-II and ⁶⁸ Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm. <i>American Journal of Roentgenology</i> , 2018, 211, 655-660.	1.0	22
118	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 78-82.	2.6	74
119	Prostate cancer PET tracers: essentials for the urologist. <i>Canadian Journal of Urology</i> , 2018, 25, 9371-9383.	0.0	22
120	Technical Note: Fast respiratory motion estimation using sorted singles without unlist processing: A feasibility study. <i>Medical Physics</i> , 2017, 44, 1632-1637.	1.6	6
121	Hybrid ^{ZTE} /Dixon ^{MR} -based attenuation correction for quantitative uptake estimation of pelvic lesions in ^{PET} / ^{MRI} . <i>Medical Physics</i> , 2017, 44, 902-913.	1.6	73
122	Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement. <i>Abdominal Radiology</i> , 2017, 42, 870-876.	1.0	24
123	¹⁸ F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. <i>Radiology</i> , 2017, 284, 460-467.	3.6	73
124	Quantitative Evaluation of Atlas-based Attenuation Correction for Brain PET in an Integrated Time-of-Flight PET/MR Imaging System. <i>Radiology</i> , 2017, 284, 169-179.	3.6	19
125	⁶⁸ Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024.	3.3	589
126	Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. <i>European Journal of Radiology</i> , 2017, 88, 117-128.	1.2	56

#	ARTICLE	IF	CITATIONS
127	Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e218-e220.	0.7	24
128	Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 376-381.	0.5	9
129	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	2.8	111
130	Evaluation of Sinus/Edge-Corrected Zero-Echo-Time-Based Attenuation Correction in Brain PET/MRI. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1873-1879.	2.8	40
131	SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 11-12.	2.8	3
132	Impact of ⁶⁸ Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1956-1961.	2.8	111
133	PET/MRI: Where might it replace PET/CT?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1247-1262.	1.9	175
134	PET/MRI: Where might it replace PET/CT?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, spcone.	1.9	2
135	The Role of PET/MR Imaging in Precision Medicine. <i>PET Clinics</i> , 2017, 12, 489-501.	1.5	7
136	PET/MR Imaging in Gynecologic Oncology. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2017, 25, 667-684.	0.6	21
137	⁶⁸ Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. <i>Journal of Nuclear Medicine</i> , 2017, 58, 81-84.	2.8	166
138	Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors. <i>Clinical and Translational Imaging</i> , 2017, 5, 63-69.	1.1	10
139	Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. <i>EJNMMI Research</i> , 2017, 7, 77.	1.1	33
140	Combined parenchymal and vascular imaging: High spatiotemporal resolution arterial evaluation of hepatocellular carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 859-865.	1.9	12
141	Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. <i>Abdominal Radiology</i> , 2016, 41, 963-969.	1.0	73
142	Comparison of diffusion-weighted imaging and T2-weighted single shot fast spin-echo: Implications for LI-RADS characterization of hepatocellular carcinoma. <i>Magnetic Resonance Imaging</i> , 2016, 34, 915-921.	1.0	11
143	Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. <i>Abdominal Radiology</i> , 2016, 41, 2161-2168.	1.0	12
144	Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. <i>Future Oncology</i> , 2016, 12, 2393-2396.	1.1	3

#	ARTICLE	IF	CITATIONS
145	Safety and technique of ferumoxytol administration for MRI. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 2107-2111.	1.9	171
146	Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. <i>Surgery</i> , 2016, 160, 747-754.	1.0	27
147	Radiation dosimetry of ⁶⁸ Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1611-1620.	3.3	143
148	Transient washout of hepatic hemangiomas: Potential pitfall mimicking malignancy. <i>Radiology Case Reports</i> , 2016, 11, 62-66.	0.2	4
149	Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent. <i>Abdominal Radiology</i> , 2016, 41, 1522-1531.	1.0	9
150	Detection of Small Pulmonary Nodules with Ultrashort Echo Time Sequences in Oncology Patients by Using a PET/MR System. <i>Radiology</i> , 2016, 278, 239-246.	3.6	124
151	Somatostatin Imaging of Neuroendocrine-Differentiated Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, 540-541.	0.7	13
152	Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. <i>EJNMMI Physics</i> , 2015, 2, 21.	1.3	27
153	Greater asymmetric wall shear stress in Sievers' type 1/LR compared with 0/LAT bicuspid aortic valves after valve-sparing aortic root replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 59-68.	0.4	36
154	Transient Respiratory Motion Artifact During Arterial Phase MRI With Gadoxetate Disodium: Risk Factor Analyses. <i>American Journal of Roentgenology</i> , 2015, 204, 1220-1227.	1.0	55
155	Simultaneous ⁶⁸ Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. <i>Abdominal Imaging</i> , 2015, 40, 1432-1440.	2.0	91
156	Vascular Imaging With Ferumoxytol as a Contrast Agent. <i>American Journal of Roentgenology</i> , 2015, 205, W366-W373.	1.0	104
157	Hepatobiliary agents and their role in LI-RADS. <i>Abdominal Imaging</i> , 2015, 40, 613-625.	2.0	105
158	MR Imaging of Diffuse Liver Disease. <i>Radiologic Clinics of North America</i> , 2014, 52, 709-724.	0.9	23
159	Neuroendocrine Tumors. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 898-914.	0.5	6
160	Evaluation of Marfan patients status post valve-sparing aortic root replacement with 4D flow. <i>Magnetic Resonance Imaging</i> , 2013, 31, 1479-1484.	1.0	27
161	Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. <i>Magnetic Resonance Imaging</i> , 2013, 31, 139-144.	1.0	8
162	Functional and molecular imaging techniques in aortic aneurysm disease. <i>Current Opinion in Cardiology</i> , 2013, 28, 609-618.	0.8	11

#	ARTICLE	IF	CITATIONS
163	Improvement of gadoxetate arterial phase capture with a high spatio-temporal resolution multiphase three-dimensional SPGR Dixon sequence. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 938-945.	1.9	27
164	Gadolinium Accumulation and Fibrosis in the Liver after Administration of Gadoxetate Disodium in a Rat Model of Active Hepatic Fibrosis. <i>Radiology</i> , 2012, 264, 423-427.	3.6	11
165	Intravenous Vasopressin for the Prevention of Nontarget Gastrointestinal Embolization during Liver-directed Cancer Treatment: Experimental Study in a Porcine Model. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1505-1512.	0.2	4
166	Improved Risk Assessment for Abdominal Aortic Aneurysm Rupture. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2531-2532.	1.2	5
167	4D Flow CMR in Assessment of Valve-Related Ascending Aortic Disease. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 781-787.	2.3	231
168	Impaired social recognition memory in recombination activating gene 1-deficient mice. <i>Brain Research</i> , 2011, 1383, 187-195.	1.1	37
169	Evaluation of intracranial stenoses and aneurysms with accelerated 4D flow. <i>Magnetic Resonance Imaging</i> , 2010, 28, 41-46.	1.0	79
170	Through Neural Stimulation to Behavior Manipulation: A Novel Method for Analyzing Dynamical Cognitive Models. <i>Cognitive Science</i> , 2010, 34, 406-433.	0.8	13
171	Four-Dimensional Flow Magnetic Resonance Imaging With Wall Shear Stress Analysis Before and After Repair of Aortopulmonary Fistula. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 766-768.	1.3	10
172	Bicuspid Aortic Valve: Four-dimensional MR Evaluation of Ascending Aortic Systolic Flow Patterns. <i>Radiology</i> , 2010, 255, 53-61.	3.6	364
173	Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. <i>Radiology</i> , 2009, 253, 390-398.	3.6	22
174	Hemodynamics in normal cerebral arteries: qualitative comparison of 4D phase-contrast magnetic resonance and image-based computational fluid dynamics. <i>Journal of Engineering Mathematics</i> , 2009, 64, 367-378.	0.6	63
175	Initial experience characterizing a type I endoleak from velocity profiles using time-resolved three-dimensional phase-contrast MRI. <i>Journal of Vascular Surgery</i> , 2009, 49, 1580-1584.	0.6	13
176	Nephrogenic Systemic Fibrosis in Patients With Chronic Kidney Disease Who Received Gadopentetate Dimeglumine. <i>Investigative Radiology</i> , 2009, 44, 135-139.	3.5	52
177	Imaging of the Thoracic Aorta with Time-Resolved Three-Dimensional Phase-Contrast MRI: A Review. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 358-364.	0.4	24
178	Evaluation of Bicuspid Aortic Valve and Aortic Coarctation With 4D Flow Magnetic Resonance Imaging. <i>Circulation</i> , 2008, 117, 2818-2819.	1.6	64